Aim: The aim of this paper is to determine the tolerability and safety of treatment for Alzheimer's dementia, especially because this therapy is mainly reserved for the elderly population, ie the risk group of patients often associated with multimorbidities and polypharmacy, and to look at the importance of the role that pharmacists, as the most accessible health professionals, can play in the treatment of Alzheimer’s dementia and the use of antidementia drugs. Subjects and method: For the purposes of this research, a systematic and retrospective review of scientific and professional literature was made and the currently valid therapeutic guidelines, publications of professional associations and institutions, the drug database of the Agency for Medicinal Products and Medical Devices and other available sources were searched. Results: The most common side effects of acetylcholinesterase inhibitors are gastrointestinal in nature and include nausea, vomiting, weight loss and diarrhea. Rivastigmine showed the highest frequency of side effects among them, while donepezil was associated with the lowest rate of side effects. They usually occur at the beginning of therapy and are mild and often transient. More intense side effects occur at higher doses and are often associated with incorrect initial drug titration. Side effects of memantine are relatively rare and well tolerated, and most commonly include constipation, dizziness, headache, and confusion. It turns out that they are also mild and transient. Conclusion: The identification of the most common side effects of each of the approved drugs for the treatment of Alzheimer's dementia, including donepezil, rivastigmine and memantine, showed that the side effects of these drugs are relatively rare and mild and transient, so we can conclude that antidementia drugs are generally well tolerated. Improving the quality of life of patients with Alzheimer's dementia and their carers is extremely important, so pharmacists, as the most accessible health professionals who are often in contact with these patients and / or their carers, must have adequate knowledge to identify existing and potential therapeutic problems, including side effects of antidementia drugs, and make interventions to provide safe and effective pharmacotherapy.